Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ATNM logo

Actinium Pharmaceuticals Inc (ATNM)ATNM

Upturn stock ratingUpturn stock rating
Actinium Pharmaceuticals Inc
$1.93
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/06/2024: ATNM (2-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: 78.69%
Upturn Advisory Performance Upturn Advisory Performance4
Avg. Invested days: 42
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 4
Last Close 11/06/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: 78.69%
Avg. Invested days: 42
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 4
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/06/2024
Upturn Advisory Performance Upturn Advisory Performance4

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 58.57M USD
Price to earnings Ratio -
1Y Target Price 5.8
Dividends yield (FY) -
Basic EPS (TTM) -1.51
Volume (30-day avg) 253708
Beta 0.14
52 Weeks Range 1.33 - 10.24
Updated Date 11/5/2024
Company Size Small-Cap Stock
Market Capitalization 58.57M USD
Price to earnings Ratio -
1Y Target Price 5.8
Dividends yield (FY) -
Basic EPS (TTM) -1.51
Volume (30-day avg) 253708
Beta 0.14
52 Weeks Range 1.33 - 10.24
Updated Date 11/5/2024

Earnings Date

Report Date 2024-10-31
When BeforeMarket
Estimate -
Actual -
Report Date 2024-10-31
When BeforeMarket
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -57665.44%

Management Effectiveness

Return on Assets (TTM) -30.91%
Return on Equity (TTM) -87.96%

Revenue by Products

Valuation

Trailing PE -
Forward PE 6.84
Enterprise Value -25617774
Price to Sales(TTM) 723.09
Enterprise Value to Revenue 1726.07
Enterprise Value to EBITDA -3.62
Shares Outstanding 31154400
Shares Floating 30368663
Percent Insiders 2.04
Percent Institutions 29.04
Trailing PE -
Forward PE 6.84
Enterprise Value -25617774
Price to Sales(TTM) 723.09
Enterprise Value to Revenue 1726.07
Enterprise Value to EBITDA -3.62
Shares Outstanding 31154400
Shares Floating 30368663
Percent Insiders 2.04
Percent Institutions 29.04

Analyst Ratings

Rating 4.33
Target Price 27.6
Buy 2
Strong Buy 3
Hold 1
Sell -
Strong Sell -
Rating 4.33
Target Price 27.6
Buy 2
Strong Buy 3
Hold 1
Sell -
Strong Sell -

AI Summarization

Actinium Pharmaceuticals Inc: A Comprehensive Overview

Company Profile:

History and Background:

Actinium Pharmaceuticals Inc. (NYSE American: ATNM) is a clinical-stage biopharmaceutical company specializing in developing targeted radiotherapies for the treatment of various cancers. Founded in 2005, the company has leveraged its Alpha-Particle Immunotherapy (APIT) platform to build a robust pipeline of novel radiopharmaceuticals.

Core Business Areas:

Actinium focuses on three core business areas:

  • Hematologic Malignancies: Currently, Actinium's lead program is Iomab-B, a targeted alpha-particle therapy for the treatment of relapsed or refractory acute myeloid leukemia (AML).
  • Solid Tumors: The company is also developing targeted alpha-therapies for solid tumors, including lung cancer and melanoma.
  • Alpha-Particle Immunotherapy (APIT) Platform: Actinium's proprietary APIT platform utilizes alpha-emitting isotopes to deliver targeted radiation directly to cancer cells while minimizing damage to healthy tissues.

Leadership Team and Corporate Structure:

The company's leadership team comprises experienced professionals with extensive expertise in oncology, drug development, and business management. Sandra S. Newman leads the company as President and CEO, while Michael J. Borin serves as Chief Financial Officer. Actinium's Board of Directors includes individuals with diverse backgrounds in finance, healthcare, and science.

Top Products and Market Share:

Top Products:

  • Iomab-B: This targeted alpha-particle therapy is currently in Phase III clinical trials for the treatment of relapsed or refractory AML. It holds Orphan Drug designation in the United States and Europe.
  • Actimab-A: This targeted alpha-particle therapy is in Phase II clinical trials for the treatment of locally advanced or metastatic melanoma.

Market Share:

Iomab-B's market share within the AML treatment landscape is currently limited as it is still in the clinical trial stage. However, if approved, it could potentially capture a significant share of the market for relapsed/refractory AML, estimated to be worth around $1 billion globally.

Comparison to Competitors:

Actinium faces competition from other companies developing targeted alpha-therapies and traditional chemotherapy treatments for AML and other cancers. Some key competitors include Bayer (BAYRY), Pfizer (PFE), and Novartis (NVS).

Total Addressable Market:

The global market for AML treatment is estimated to be around $1 billion, while the market for targeted alpha-therapies is estimated to reach $2 billion by 2025. Actinium's potential addressable market encompasses both these segments, offering significant growth opportunities.

Financial Performance:

Recent Financial Statements:

  • Revenue: Actinium is currently in the clinical development stage and has not yet generated significant revenue.
  • Net Income: The company has reported net losses in recent years due to ongoing research and development expenses.
  • Profit Margins: As a clinical-stage company, Actinium currently has negative profit margins.
  • Earnings per Share (EPS): Actinium does not have positive earnings and therefore does not report EPS.

Financial Performance Comparison:

Year-over-year comparisons are not applicable as the company is still in the early stages of development.

Cash Flow and Balance Sheet:

Actinium's cash flow is primarily driven by funding from public offerings, collaborations, and grants. The company has a limited operating history and a relatively small balance sheet.

Dividends and Shareholder Returns:

Actinium does not currently pay dividends, as it focuses on reinvesting its resources into research and development activities. Shareholder returns have been negative in recent years due to the company's early-stage development status.

Growth Trajectory:

Historical Growth:

Actinium has demonstrated significant progress in advancing its pipeline of targeted alpha-therapies through clinical trials. The company has successfully completed several Phase I and II trials and is currently conducting Phase III trials for its lead program, Iomab-B.

Future Growth Projections:

Analysts project robust growth for Actinium if its lead candidate, Iomab-B, receives regulatory approval. The successful commercialization of Iomab-B could significantly boost the company's revenue and market value.

Growth Drivers:

  • Positive clinical trial results: Continued success in clinical trials, particularly for Iomab-B, will be crucial for driving future growth.
  • Regulatory approvals: Obtaining regulatory approvals for its targeted alpha-therapies will enable Actinium to commercialize its products and generate revenue.
  • Strategic partnerships: Collaboration with larger pharmaceutical companies could provide Actinium with additional funding and expertise for further development and commercialization.

Market Dynamics:

Industry Overview:

The market for cancer treatments is constantly evolving with advancements in targeted therapies, immunotherapy, and personalized medicine. The targeted alpha-therapy market is a promising segment gaining traction due to its potential for improved efficacy and reduced side effects compared to traditional chemotherapy.

Market Position:

Actinium is a pioneer in the development of targeted alpha-therapies and holds a strong position in this emerging market. The company's APIT platform offers a unique approach to cancer treatment with the potential to address unmet medical needs.

Adaptability to Market Changes:

Actinium actively monitors industry trends and adapts its strategies accordingly. The company continuously invests in research and development to stay at the forefront of innovation and respond to evolving market demands.

Competitors:

  • Bayer (BAYRY): Develops Xofigo, a targeted alpha-therapy for castration-resistant prostate cancer.
  • Pfizer (PFE): Offers Bavencio, an immunotherapy for metastatic urothelial carcinoma.
  • Novartis (NVS): Develops Kymriah, a CAR-T cell therapy for leukemia and lymphoma.

Competitive Advantages:

  • Proprietary APIT platform: Actinium's unique platform provides a competitive edge in developing targeted alpha-therapies.
  • Strong clinical pipeline: The company has a diverse pipeline of promising candidates targeting various cancers.
  • Experienced leadership team: Actinium's leadership team comprises accomplished professionals with extensive industry experience.

Competitive Disadvantages:

  • Limited commercialization experience: As a clinical-stage company, Actinium lacks experience in commercializing its products.
  • Financial constraints: Actinium's limited financial resources may hinder its ability to compete with larger pharmaceutical companies.

Potential Challenges and Opportunities:

Key Challenges:

  • Clinical trial success: The success of Actinium's clinical trials is crucial for regulatory approval and market acceptance of its products.
  • Competition: The company faces stiff competition from established pharmaceutical companies in the oncology market.
  • Funding: Actinium may require additional funding to support its ongoing clinical trials and commercialization efforts.

Opportunities:

  • Expanding market opportunities: The targeted alpha-therapy market is expected to grow significantly, offering vast potential for Actinium's products.
  • Strategic partnerships: Collaborations with larger companies could provide Actinium with additional resources and expertise for further development and commercialization.
  • Positive regulatory environment: Regulatory agencies are increasingly recognizing the potential of targeted alpha-therapies, potentially expediting the approval process for Actinium's candidates.

Recent Acquisitions (last 3 years):

Actinium has not acquired any companies in the last three years. However, the company has entered into several strategic partnerships, including a collaboration with Bayer to develop targeted alpha-therapies for solid tumors.

AI-Based Fundamental Rating:

Rating:

Based on an AI-based analysis incorporating factors such as financial health, market position, and future prospects, Actinium Pharmaceuticals receives a rating of 7 out of 10.

Justification:

  • Promising pipeline: Actinium has a diverse pipeline of targeted alpha-therapies with significant potential in the growing oncology market.
  • Strong leadership team: The company's experienced leadership team provides valuable guidance and strategic direction.
  • Market opportunity: The targeted alpha-therapy market offers significant growth potential for Actinium's products.

Areas for Improvement:

  • Commercialization experience: Actinium's lack of experience in commercializing products could pose a challenge.
  • Financial resources: The company's limited financial resources may restrict its ability to compete with larger pharmaceutical companies.
  • Clinical trial dependence: Actinium's success hinges heavily on the outcome of its clinical trials.

Sources and Disclaimers:

Sources:

  • Actinium Pharmaceuticals Inc. website (https://www.actiniumpharma.com/)
  • Securities and Exchange Commission (SEC) filings
  • Financial news articles
  • Industry reports

Disclaimers:

  • This information is for educational purposes only and should not be considered investment advice.
  • The AI-based rating is based on publicly available information and may not be entirely accurate.
  • Investors should conduct their own due diligence before making any investment decisions.

Please note that this analysis is based on the information available as of October 26, 2023.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Actinium Pharmaceuticals Inc

Exchange NYSE MKT Headquaters New York, NY, United States
IPO Launch date 2012-12-27 Chairman & CEO Mr. Sandesh C. Seth M.B.A., M.S.
Sector Healthcare Website https://www.actiniumpharma.com
Industry Biotechnology Full time employees 49
Headquaters New York, NY, United States
Chairman & CEO Mr. Sandesh C. Seth M.B.A., M.S.
Website https://www.actiniumpharma.com
Website https://www.actiniumpharma.com
Full time employees 49

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​